OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.99 EUR 3.28% Market Closed
Market Cap: 131.4m EUR

OSE Immunotherapeutics SA
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
EPS (Diluted)
€1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
EPS (Diluted)
€0
CAGR 3-Years
53%
CAGR 5-Years
-32%
CAGR 10-Years
15%
G
Genfit SA
PAR:GNFT
EPS (Diluted)
€0
CAGR 3-Years
-71%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
EPS (Diluted)
-€3
CAGR 3-Years
-34%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
EPS (Diluted)
$0
CAGR 3-Years
32%
CAGR 5-Years
31%
CAGR 10-Years
5%
Eurobio Scientific SA
PAR:ALERS
EPS (Diluted)
€0
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

OSE Immunotherapeutics SA
Glance View

Market Cap
130.8m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
3.74 EUR
Overvaluation 38%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's EPS (Diluted)?
EPS (Diluted)
1.5 EUR

Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's EPS (Diluted) amounts to 1.5 EUR.

Back to Top